Duloxetine Hydrochloride Enteric Capsules — Competitive Intelligence Brief

Duloxetine Hydrochloride Enteric Capsules (Duloxetine Hydrochloride Enteric Capsules) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin-norepinephrine reuptake inhibitor (SNRI). Area: Psychiatry / Pain Management.

phase 3 Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin transporter (SERT) and norepinephrine transporter (NET) Psychiatry / Pain Management Small molecule

Target snapshot

Duloxetine Hydrochloride Enteric Capsules (Duloxetine Hydrochloride Enteric Capsules) — Zhejiang Huahai Pharmaceutical Co., Ltd.. Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases levels of serotonin and norepinephrine in the central nervous system by blocking their reuptake at the presynaptic membrane.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Duloxetine Hydrochloride Enteric Capsules TARGET	Duloxetine Hydrochloride Enteric Capsules	Zhejiang Huahai Pharmaceutical Co., Ltd.	phase 3	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT) and norepinephrine transporter (NET)
Pristiq	Desvenlafaxine Succinate	Pfizer	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin and norepinephrine reuptake	2008-01-01
Effexor	Venlafaxine Hydrochloride	Pfizer	marketed	Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)	Serotonin and norepinephrine reuptake transporters	1993-01-01
Venlafaxine IR and Venlafaxine XR	Venlafaxine IR and Venlafaxine XR	North Dakota State University	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT) and norepinephrine transporter (NET)
Treatment (Viibryd)	Treatment (Viibryd)	Southern California Institute for Research and Education	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI) with 5-HT1A partial agonist activity	Serotonin transporter (SERT); 5-HT1A receptor (partial agonist)
toludesvenlafaxine hydrochloride sustained-release tablets	toludesvenlafaxine hydrochloride sustained-release tablets	Shanghai Mental Health Center	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT) and norepinephrine transporter (NET)
Aripiprazole + desvenlafaxine succinate sustained release	Aripiprazole + desvenlafaxine succinate sustained release	Pfizer	marketed	Atypical antipsychotic + serotonin-norepinephrine reuptake inhibitor (SNRI) combination	Dopamine D2/D3 receptors (aripiprazole); serotonin transporter (SERT) and norepinephrine transporter (NET) (desvenlafaxine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin-norepinephrine reuptake inhibitor (SNRI) class)

1. Pfizer · 3 drugs in this class
2. Wyeth is now a wholly owned subsidiary of Pfizer · 3 drugs in this class
3. National Institute of Mental Health (NIMH) · 2 drugs in this class
4. Zhejiang Huahai Pharmaceutical Co., Ltd. · 2 drugs in this class
5. Eli Lilly and Company · 2 drugs in this class
6. New York State Psychiatric Institute · 1 drug in this class
7. North Dakota State University · 1 drug in this class
8. Ministry of Health & Welfare, Korea · 1 drug in this class
9. Purdue Pharma, Canada · 1 drug in this class
10. Shanghai Mental Health Center · 1 drug in this class